Glaukos Board Chairman Dr. William J. Link to Retire at Year’s End

Ophthalmic technology and pharmaceutical firm Glaukos Board Chairman William J. Link, Ph.D. will retire effective December 31. Dr. Link joined the Board and has been chairman since June 2001.
 
The Board subsequently appointed Glaukos president and CEO Thomas W. Burns as Board Chairman upon Dr. Link’s retirement. Burns has been a Board director for Glaukos since 2002. He will continue to serve as the company’s president and CEO.
 
Glaukos also named Board member and chair of the Compensation, Nominating, and Governance Committee Mark J. Foley as the Board’s lead independent director.
 
“We’re grateful for Bill’s leadership and contributions over the past 20 years, helping to guide Glaukos’ transformational evolution from an early-stage startup into a global, diversified, ophthalmic drug and device leader,” Foley told the press. “The Board believes Tom is an ideal fit to serve as the company’s next Chairman and is confident he will continue to successfully lead Glaukos forward in its next phase of innovation and growth.
 
“It’s been my privilege to serve Glaukos and its many stakeholders, and I am grateful to the Board and my colleagues, both past and present, for their support during my tenure,” said Dr. Link. “Glaukos will be in great hands with Tom’s continued leadership and is well-positioned to drive meaningful innovation to address unmet needs in large and underserved patient populations suffering from chronic eye diseases.”
 
“On behalf of the entire Glaukos organization, I am deeply grateful to Bill for his unwavering commitment and decades of dedicated leadership and service to Glaukos. His guidance, vision and expertise have been instrumental to Glaukos’ growth and development,” said Burns. “It’s my honor to continue working alongside the Board and our global teams as we continue to advance our mission to transform the treatment of chronic eye diseases for the benefit of patients worldwide.”